Iprasure Pulmicaps 100mcg/40mcg Capsule is a combination bronchodilator containing Salbutamol sulfate (100mcg) and Ipratropium bromide (40mcg), indicated for the management of chronic obstructive pulmonary disease (COPD) and asthma. Salbutamol is a selective β2-adrenergic receptor agonist that provides rapid bronchodilation by relaxing bronchial smooth muscle, thereby alleviating bronchospasm and improving airflow. Ipratropium is an anticholinergic agent that blocks muscarinic receptors in the airways, reducing bronchoconstriction and mucus secretion. The synergistic action of these two agents results in enhanced bronchodilation and symptomatic relief in obstructive airway diseases. Iprasure Pulmicaps are typically administered via inhalation, allowing targeted delivery to the lungs with minimal systemic absorption, thus reducing the risk of systemic side effects. This combination is particularly beneficial in patients who do not achieve adequate control with monotherapy. It is essential to use this medication under medical supervision, adhering to prescribed dosages to avoid potential adverse effects such as tachycardia, dry mouth, or tremors. Iprasure Pulmicaps should be used as part of a comprehensive treatment plan including avoidance of triggers and regular monitoring of pulmonary function.